Reata raises $78 million to fund second pivotal bardoxolone trial as it seeks European partner
This article was originally published in Scrip
Executive Summary
Reata Pharmaceuticals has raised $78 million to fund the second of two pivotal trials of its lead product candidate bardoxolone methyl (RTA 402) in patients with advanced chronic kidney disease (CKD) and type 2 diabetes.